Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Holmberg

Showing results (431-440 of 509) with videos related to

Pageof 51
Sort By:
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWDJ Eikenboom, V Van Marion, H Putter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myelomaW I Bensinger, S D Rowley, T Demirer, et al.
Journal of Thrombosis and Haemostasis : JTH|April 6, 2007
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD)A Tosetto, F Rodeghiero, G Castaman, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)U Budde, R Schneppenheim, J Eikenboom, et al.
Bone Marrow Transplantation|September 28, 2011
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myelomaO Ringdén, S Shrestha, G T da Silva, et al.
JAMA|February 28, 1998
Alcohol and breast cancer in women: a pooled analysis of cohort studiesS A Smith-Warner, D Spiegelman, S S Yaun, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 31, 2025
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell LymphomaM Ebadi, X Fan, G Schoch, et al.
Bone Marrow Transplantation|June 1, 1996
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant diseaseK S Schiffman, W I Bensinger, F R Appelbaum, et al.
Journal of Thrombosis and Haemostasis : JTH|August 8, 2006
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand FactorJ E Sadler, U Budde, J C J Eikenboom, et al.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Pageof 51

Showing results (431-440 of 509) with videos related to

Sort By:
Pageof 51
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWDJ Eikenboom, V Van Marion, H Putter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myelomaW I Bensinger, S D Rowley, T Demirer, et al.
Journal of Thrombosis and Haemostasis : JTH|April 6, 2007
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD)A Tosetto, F Rodeghiero, G Castaman, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)U Budde, R Schneppenheim, J Eikenboom, et al.
Bone Marrow Transplantation|September 28, 2011
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myelomaO Ringdén, S Shrestha, G T da Silva, et al.
JAMA|February 28, 1998
Alcohol and breast cancer in women: a pooled analysis of cohort studiesS A Smith-Warner, D Spiegelman, S S Yaun, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 31, 2025
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell LymphomaM Ebadi, X Fan, G Schoch, et al.
Bone Marrow Transplantation|June 1, 1996
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant diseaseK S Schiffman, W I Bensinger, F R Appelbaum, et al.
Journal of Thrombosis and Haemostasis : JTH|August 8, 2006
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand FactorJ E Sadler, U Budde, J C J Eikenboom, et al.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Pageof 51